Freedom Leaf Inc (OTCMKTS:FRLF) Acquires Green Market Europe

Freedom Leaf Inc (OTCMKTS:FRLF)

Freedom Leaf Inc (OTCMKTS:FRLF), which focuses on marijuana industry mergers and acquisitions, has signed an intent letter of acquisition with Green Market Europe owners. The acquisition will see Freedom Leaf take ownership of an operational greenhouse that measures more than 60,000 square feet. Shares of Freedom Leaf fell by 1.94% to $0.0505 on Thursday.

The greenhouse consists of more than 20,000 square feet equipped with a light deprivation system necessary for the stimulation of flowering throughout the year. An additional 200 acres are also available for outdoor production and thus the capacity for both outdoor and greenhouse production can be scaled up if necessary.

No debt

All the facilities that will be acquired from Green Market Europe are free of debt. The acquisition will include all assets belonging to Green Market Europe such as purchase orders that are more than $450,000, production agreements with local farmers, intellectual property, greenhouse equipment, leasehold improvements, and land leases.

The chief executive officer and co-founder of Freedom Leaf Inc (OTCMKTS:FRLF), Clifford Perry, said the acquisition would turn the company into a major player in the industry.

“With this transformative acquisition Freedom Leaf has become a major participant not only in the booming CBD (cannabidiol) industry, but in many other aspects of the global hemp industry,” said Perry.

Some of the development projects that Freedom Leaf Inc (OTCMKTS:FRLF) is engaged in includes rare cannabinoids research. Hemp seed oil, making furniture and footwear from fabric derived from hemp, phytocannabinoid oil, and CBD drinks.

Spanish Mediterranean coast

Miguel Hernandez University, an institution which possesses extensive facilities for research and development, is collaborating with Green Market Europe in fertilizer testing projects, LED growing systems, and genetic breeding.

Operations are in the Callosa de Segura area of Alicante, Spain and close to Elche city on the southeastern Mediterranean coast. Due to the favorable and moderate climate, multiple crops can be produced every year.

Natural Hemp was started in 2013 by Vicente Javaloyes Martinez and Luis Miguel Santos is the predecessor of Green Market Europe.

One of the agreements contained in the intent letter is that the current management of Green Market Europe will be retained. The acquisition will consist of a common stock transaction of 4,800,000 shares belonging to Freedom Leaf as well as 20,000 euros in cash. Shareholders of Green Market Europe will get to keep half of the profits that have been generated. The flagship publication of Freedom Leaf Inc (OTCMKTS:FRLF) is Freedom Leaf Magazine.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $FRLF and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Marc worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Shares Rocket for CHF Solutions, Inc. (NASDAQ:CHFS)

CHF Solutions, Inc. (NASDAQ:CHFS) – formerly Sunshine Heart Inc.

CHF Solutions, Inc. (NASDAQ:CHFS) closed Thursday at $1.08 and gapped up to open at $1.29 before hitting their inter-day high of $1.65 – a gain of over 40%. Volumes are extraordinarily heavy. The 50-day, daily trading average is listed at just over 550,000 shares but already over 13.8 million shares of CHFS have traded hands. The market is responding to a news release by CHF Solutions that researchers in the Stanford University School of Medicine’s Department of Pediatrics have received FDA Investigational Device Exemption (IDE) approval to conduct a clinical study to evaluate the safety and effectiveness of CHF Solutions’ Aquadex FlexFlow Aquapheresis System for diuretic-resistant fluid overload in children with acute decompensated heart failure. Patients suffering from this condition have typically failed diuretic therapy and require hospitalization.

CHF Solutions, Inc. (NASDAQ:CHFS) was formerly known as Sunshine Heart Inc. and is based out of Eden Prairie, MN. In April, Sunshine Heart Inc. (NASDAQ:SSH) shares plummeted on news of the company’s pricing regarding a public share offering. Dilution has been a long-time concern for shareholders as the dilution adjusted share price in 2014 is calculated at over $200. While the nano-cap medical device firm has a market-cap under $15 million, for FY2016 the company reported a net loss applicable to shareholders of over $15 million – in 215 that loss was a larger loss of over $26 million.

Despite these performances, the sole investment firm, Cowen & Company, that follows CHF Solutions, Inc. (NASDAQ:CHFS) rates CHFS shares as a “Strong Buy” with a price target of $6.125.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CHFS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Marc worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

NEXOPTIC TECHNOLOGY (OTCMKTS:NXOPF) Working On A Smartphone Telephoto Lens System

NEXOPTIC TECHNOLOGY (OTCMKTS:NXOPF)

NEXOPTIC TECHNOLOGY (OTCMKTS:NXOPF) traded higher by 5.53% in Thursday’s trading session after announcing it had received a Notice of Allowance from the United States Patent and Trademark Office (USPTO). The stock closed at $1.09. The Notice is for a patent application filed by Spectrum Optix Inc. for the Blade Optics Lens technology. Spectrum Optix is a private corporation but NexOptic has an option to acquire the company. Each of the two firm’s CEO sits on each other Board of Directors.

Blade Optics Lens Patent

The two companies expect the USPTO to issue the patent over the next 4-8 weeks. Spectrum has also filed patent applications for the technology in other key international markets.

“Securing a patent for Blade Optics™, our platform suite of lens design technologies, is a major step toward implementing our global growth and commercialization strategy,” said John Daugela, President of Spectrum Optix and Director of NexOptic.

NEXOPTIC TECHNOLOG COM NPV (OTCMKTS:NXOPF) and Spectrum Optix expect Blade Optics to break down common limitations associated with curved lens stacks.

Telephoto Lens Development

The two companies are fresh from completing an engineering trade study of a telephoto lens stack design intended for smartphones. The lens stack design builds on the benefits of the fundamental ‘compress before focus’ principle to generate high-quality images. Spectrum has already filed patent protection for the new design.

The telephoto lens stack design features a large aperture that has the potential to provide high resolution and long range for use in mobile devices. A number of designs have already been developed that the two companies say satisfy a variety of technical specifications in relation to focal length, field of view, aperture and sensor requirements.

Initial simulations indicate that the new telephoto lens design can improve angular resolution in existing smartphone lens systems. The design has the potential to double light gathering area from leading smartphone lens systems.

Spectrum Optix is currently working on the second phase of the prototype development program for mobile devices. In the second phase, the company plans to refine specifications based on industry feedback as well as completing detailed optical designs and defining lens tolerance.

The engineering trade study marks the first step in the two companies push to expand their technology pipeline. The two companies remain confident of delivering a telephoto lens system that can capture better images of objects at a distance than what is currently available. Changing the way smartphones captures images at a distance is the core objective with this telephoto lens design.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $NXOPF and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

NXT-ID Inc. (NASDAQ:NXTD) Shares Power Higher

NXT-ID Inc. (NASDAQ:NXTD)

Shares of NXT-ID Inc. (NASDAQ:NXTD) were up by more than 70%, after the company’s Fit Pay subsidiary announced it has started to offer payment capabilities for Token – a biometric identity ring designed to streamline the process of identification authentication. Token is available for pre-sale at $249.

Technology Validation

NXT-ID Inc. (NASDAQ:NXTD) is a provider of payment and authentication platform services. The company boasts of extensive experience in access control and behavior metric identity verification. Providing payment capabilities for Token validates NXT-ID’s comprehensive platform that currently offers technology products and services for the internet of things.

NXT-ID Inc. (NASDAQ:NXTD) boasts of three mobile and IoT subsidiaries. LogicMark LLC spearheads the company’s efforts in the development of non-monitored and monitored personnel emergency services. Its services are normally sold through dealers and the Department of Veteran Affairs.

FitPay is a subsidiary that is strengthening NXT-ID Inc. (NASDAQ:NXTD) foothold in the payments and Internet of Things. The unveiling of Token offers a glimpse of how the company plans to transform the payment experience for consumers through secure authentication and frictionless transaction.

“Our vision is to offer a device that streamlines the process of authentication throughout the day, while simultaneously protecting users from identity fraud using advanced cryptography,” said Token Cofounder and CEO, Melanie Shapiro.

Token replaces credentials needed to carry out daily transactions such as credit cards, house keys, and passwords. It leverages a proprietary two-factor authentication method via a fingerprint sensor in the base of a ring and an optical proximity sensor. Token also uses a payment security technology that replaces cardholder’s account information with a unique identifier designed to facilitate secure contactless payment authentication services.

NXT-ID Inc. (NASDAQ:NXTD) will now be able to target wearable device manufacturers with the new payment technology. Device manufacturers can add the payment solutions and authentication capabilities to their products with no investment or start-up time needed.

Fly Smart Cards Milestone

Separately, NXT-ID Inc. (NASDAQ:NXTD) says it has delivered about 60,000 Flye smart cards to WorldVentures, a leading direct seller. The company touts the Flye smart cards as the world’s most cutting-edge technology designed to provide convenience and unprecedented security.

The smart cards were specifically developed for the distributor’s DreamTrips, a travel club and entertainment community. Flye First is currently available to members in Singapore and South Africa ahead expected launch in Budapest.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $NXTD and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

SARISSA RESOURCES COM STK USD0.001 (OTCMKTS:SRSR) Explodes On RP Capital Investment In Nemegosenda Project

SARISSA RESOURCES COM STK USD0.001 (OTCMKTS:SRSR)

SARISSA RESOURCES COM STK USD0.001 (OTCMKTS:SRSR) stock rallied by 125% to end the day at $0.009 a share, after the mining company announced it reached an agreement with RP Capital for the development of Nemegosenda Specialty Metal project. The massive rally on huge volume came as a surprise given that the stock has been dead silent in recent trading sessions.

Niobium Prospects

SARISSA RESOURCES COM STK USD0.001 (OTCMKTS:SRSR) is a mining company with properties in Northern Ontario Canada. Its primary project is the Nemegosenda niobium project that consists of 9,000 mining claims. The company is developing the project as part of an effort that seeks to address the growing demand for Niobium in addition to pursuing shareholder value.

Industry sources indicate that demand for Niobium will continue to grow. Given the fact that there are only 3 significant producers of the chemical component, SARISSA RESOURCES COM STK USD0.001 (OTCMKTS:SRSR) has an opportunity to generate significant value from the mine.

RP Capital group is an international investment firm based in Montreal. The firm is reportedly well positioned to provide the junior mining company with the much-needed expertise and capital required for the project’s success.

Partnership Terms

Under the terms of the agreement, RP Capital Group is to invest $C250,000 into the Nemegosenda Specialty project. The investment firm is also to provide an additional $C250,000 once certain project milestones are met. In addition to capital investments, the firm is also to help in executive recruitment and legal matters – amongst other business services.

RP Capital’s investment will be in the form of a Secured Convertible Loan that will convert into a 35% stake in the Nemegosenda project.

“The addition of RP Capital Group to the Nemegosenda project is the game changing event we have been working to secure for the company. The project will now have availability to the business and mining expertise as well as the capital necessary to rapidly move the project forward,” said Dan Byrness, SARISSA RESOURCES COM STK USD0.001 (OTCMKTS:SRSR) President.

The signing of the agreement with RB Capital follows the termination of a previously announced agreement for the sale of the Nemegosenda specialty rare earth project. The company has since reiterated plans to expedite the development of the project in partnership with its subsidiary Nio-Star.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $SRSR and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Earth Science Tech Inc (OTCMKTS:ETST) $4.12 Price Target Spooks Investors

Earth Science Tech Inc (OTCMKTS:ETST)

Earth Science Tech Inc (OTCMKTS:ETST) stock tumbled by 13.67% in Thursday’s trading session after independent equity research firm, SeeThruEquity, initiated coverage of the stock with a share price target of $4.12. The stock ended the day at $0.820 a share as the high valuation caught investors by surprise.

$4.12 Valuation

The equity research firm in its research note says it sees Earth Science Tech Inc (OTCMKTS:ETST) as a high risk and high reward play given its burgeoning prospects in legal cannabis and hemp industry. The company is also pursuing opportunities for growth on nutraceuticals, pharmaceuticals, and medical devices development.

The SeeThruEquity $4.12 price target assumes that Earth Science Tech Inc (OTCMKTS:ETST) will be successful in the new product launches that are key to the company’s growth strategy. The research firm also believes aggressive marketing campaigns will give the company’s products an edge in the market leading to sales growth.

However, the firm has warned that regulatory changes, especially in the cannabis space, could significantly hurt Earth Science Tech Inc (OTCMKTS:ETST) growth prospects.

“Our team is passionate and truly believes in our brand. We truly believe ETST will emerge as a leading biotech, and most importantly, we plan to keep helping individuals to positively change and improve their lives,” said Earth Science Tech Inc (OTCMKTS:ETST) President, Nickolas S. Tabraue.

The SeeThruEquity valuation is based on the existing legal cannabis market. The Nutraceuticals that Earth Sciences is currently developing have already proved to be capable of treating arthritis and chronic pain. Those markets are worth more than $7 billion.

Robust Pipeline

Earth Science Tech Inc (OTCMKTS:ETST) boasts of a robust pipeline of nutraceuticals supplements as well as pharmaceuticals. The company plans to launch three sports supplements this year and two CBD based drugs in the first quarter of next year. A new e-liquid and edible gummies should be ready for sale in the third quarter.

The biotech company recently launched a new flavored CBD oil, organic chocolate CBD, and pet CBD that it expects to drive revenues heading into 2018. Sales for organic chocolates have been impressive with the company’s “Orange Blossom” receiving praise as the best CBD oil available in the market.

Earth Science Tech Inc (OTCMKTS:ETST) has also inked strategic partnerships with Karmavore Superfoods, Forzagen, and Smart medicines as part an effort that seeks to diversify the current product line. The company plans to venture into new markets with the support of the new partners.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ETST and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Moleculin Biotech Inc (NASDAQ:MBRX) Announces Scientific Support For Research Endeavor At Mayo Clinic

Moleculin Biotech Inc (NASDAQ:MBRX)

Moleculin Biotech Inc (NASDAQ:MBRX) announced entering into an agreement with a physician at the Mayo Clinic to perform additional research on Moleculin’s WP1066 molecule for the possible treatment of a rare form of pediatric brain tumor. Moleculin Biotech is a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates.

 Mayo Clinic physician-scientists requested, and Moleculin Biotech Inc (NASDAQ:MBRX) agreed, to supply them with WP1066 for preclinical testing for the potential treatment of pediatric Diffuse Intrinsic Pontine Gliomas (DIPG), a rare and very aggressive form of brain tumor.

Mayo Clinic studies have suggested that DIPG may be particularly sensitive to the inhibition of the activated form of a cell-signaling protein called STAT3, a primary target of WP1066, and their preliminary studies have demonstrated significant anti-tumor activity of WP1066 in DIPG in vitro and in vivo tumor models.

In a statement, Moleculin Biotech Inc (NASDAQ:MBRX) Chairman and CEO, Walter Klemp, said they are thrilled to work with The Mayo Clinic in exploring the treatment potential of WP1066in in treating DIPG. He added that this should make it easier to secure an IND to study WP1066 for the treatment of adult brain tumors.

In other news, Moleculin Biotech Inc (NASDAQ:MBRX) has announced the discovery of a metabolic inhibitor with the potential to treat pancreatic cancer. Klemp announced that the company has received a lot of attention from the scientific and medical community following the company’s glucose decoy technology as a potential means of killing tumors by exploiting their hyper-dependence on glycolysis for energy production. He added that during the pre-clinical testing, the company’s WP1234 has shown improved drug characteristics compared to WP1122 and greater ability to kill pancreatic cancer cell lines when compared with traditional inhibitors of glycolysis. Klemp said that the discovery makes WP1234 a promising solution to kill pancreatic cancer which is known to survive in reduced oxygen environment.

According to Mr. Klemp, any small gain made in treating pancreatic cancer will make a significant gain in the medical field owing to the fact that the disease is largely regarded as untreatable. WP1234 works by improving on known inhibitors for glycolysis by increasing drug circulation time, which in turn increases the potential for drug uptake by destruction of tumor cells. Mr. Klemp said the discovery is a result of his company’s collaboration with M.D. Anderson Cancer Center.

During the Wednesday session, the stock of Moleculin Biotech Inc (NASDAQ:MBRX) reported a +17.31% or +$0.021 to close the session at $0.145.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $MBRX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Sunrun Inc (NASDAQ:RUN) Nearly Doubles Addressable Market

Sunrun Inc (NASDAQ:RUN) Nearly Doubles Addressable Market

Sunrun Inc (NASDAQ:RUN) has announced that it has doubled its total addressable market (TAM) in a period of just four months. Sunrun is the largest dedicated residential solar, storage and energy services company in the United States.

Sunrun Inc (NASDAQ:RUN)
NASDAQ:RUN Daily Price graph June 29

Sunrun Inc (NASDAQ:RUN) recently expanded its reach to seven new solar markets in Florida, Washington, D.C, Wisconsin, Vermont, Texas, Rhode Island and New Mexico. In addition, the company expanded operations in Pennsylvania and re-entered the state of Nevada after policymakers passed legislation to reinstate solar net metering.

The expansions brings Sunrun Inc (NASDAQ:RUN) operations to 22 states and Washington, D.C., and offers another proof point of the inevitability of solar. It shows that tripping solar installation costs, combined with strong consumer demand for energy choice, are increasing homeowner’s access to solar power.

Recent legislative wins have proved that rooftop solar is a bipartisan issue. Lawmakers and voters across the political spectrum seem to have recognized the benefits solar energy provides by reducing energy costs for all homeowners and modernizing the energy grid.

According to Sunrun Inc (NASDAQ:RUN) CEO, Lynn Jurich, expanding to these markets will give homeowners the opportunity to power their homes directly from their rooftops, making energy affordable, and the electric grid cleaner and more reliable. He added that Sunrun is providing these services and creating jobs.

Currently, Sunrun Inc (NASDAQ:RUN) has operations in seven new states which, according to recent analysis, adds around 12 million homes that would be good candidates for solar in the states in which Sunrun operates. These new markets nearly double the company’s TAM to over 26 million homes.

The increase in new markets this year will set a foundation for 2018 and beyond, as the company plans to continue expanding into new markets. In addition, the company plans to offer its most recent innovation, Sunrun BrightBox™ solar power and energy storage service, to additional states.

Sunrun Inc (NASDAQ:RUN) shares jumped in trading Tuesday after being upgraded by an analyst. By 2:55 p.m. EDT shares were still up 10.5% on the day. Goldman Sachs‘, Brian Lee, upgraded Sunrun to a buy rating and put a $10 price target on the stock. The price target implies a 71% gain from Monday’s closing price. Some of the gain was as a result of speculation that merger and acquisition activity could pick up in the solar space.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $RUN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

 

CRITICAL OUTCOME T COM NPV (OTCMKTS:COTQF) Reverse Split

CRITICAL OUTCOME T COM NPV (OTCMKTS:COTQF)

CRITICAL OUTCOME T COM NPV (OTCMKTS:COTQF) yesterday announced, in response to the recent trading activity in its stock, that it has no material changes to report at this time. Critical Outcome Technologies believes the recent trading activity is in response to the planned share consolidation (reverse stock split) announced on June 23, 2017. Yesterday over 122,000 shares of COTQF traded. The 30-day, daily average volume is listed at only 18.114

On June 23rd that in accordance with shareholder approval obtained on October 13, 2016,the Board of Directors of CRITICAL OUTCOME T COM NPV (OTCMKTS:COTQF) has resolved to proceed with a consolidation of the Company’s issued and outstanding common shares on the basis of ten pre-consolidation common shares for one post-consolidation common share. CRITICAL OUTCOME T COM NPV (OTCMKTS:COTQF) currently has 149,158,435 issued and outstanding common shares and will have approximately 14,915,844 common shares issued and outstanding following the Consolidation.

CRITICAL OUTCOME T COM NPV (OTCMKTS:COTQF) is a clinical stage biopharmaceutical company developing new cancer treatments through targeted therapeutics. The Company’s lead compound, COTI-2, has a p53-dependent mechanism of action with selective and potent anti-cancer activity. The initial indication is in gynecologic cancers (ovarian, cervical and endometrial) that commenced a Phase 1 clinical trial in patients at MD Anderson Cancer Center in February 2016. CRITICAL OUTCOME T COM NPV (OTCMKTS:COTQF) has secured orphan drug status from the U.S. Food and Drug Administration (FDA) for the ovarian indication in the U.S. and is planning additional studies in other indications such as head & neck, AML, and Li-Fraumeni as well as combination therapies with other leading cancer drugs. Pre-clinical data provides evidence to suggest a potentially dramatic change in the treatment of cancers with mutations of the p53 gene.

During the Wednesday session, the stock of CRITICAL OUTCOME T COM NPV (OTCMKTS:COTQF) reported a +17.31% or +$0.021 to close the session at $0.145.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $COTQF and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

INNATE IMMUNOTHERA NPV (OTCMKTS:INNMF) Bounces after Crash

INNATE IMMUNOTHERA NPV (OTCMKTS:INNMF)

INNATE IMMUNOTHERA NPV (OTCMKTS:INNMF) shares bounced back after their crash earlier this week that saw INNMF shares drop by over 90% after the biotechnology company released an announcement that its lead drug candidate, MIS416, had failed to achieve any meaningful improvements in the treatment of multiple sclerosis during a Phase 2B study.

INNATE IMMUNOTHERA NPV (OTCMKTS:INNMF)
Buncing

The study was designed to evaluate the efficacy, safety, tolerability, and immune pharmacodynamics of MIS416, compared to a placebo, when weekly administered intravenously for a year. Subjects enrolled in the study were randomized (on a 2:1 ratio) to receive either MIS416 or a saline placebo. To determine the efficacy of MIS416 relative to placebo on measures of neuromuscular function, assessments were carried out at baseline, at three monthly intervals during the trial, and at end of dosing.

In related news, Congressman Chris Collins suffered a paper loss of $22 million after INNATE IMMUNOTHERA NPV (OTCMKTS:INNMF) announced negative results from a mid-stage trial of its experimental treatment for multiple sclerosis.

The New York Congressman is the biggest shareholder in INNATE IMMUNOTHERA NPV (OTCMKTS:INNMF), owning 17% of the company’s shares. After the data was reported on Tuesday, the shares fell 92% on the Australian Securities Exchange to less than 5%. INNATE IMMUNOTHERA NPV (OTCMKTS:INNMF)’s stock, sold in an initial public offering in December 2013, had gradually risen through 2016 before soaring early 2017 to peak at $1.77 on January 25.

Congressman Collins came under fire early this year for investing in the Sydney-based company while sitting on a House Committee that oversees health-care policy. Along with his shares, he sits on INNATE IMMUNOTHERA NPV (OTCMKTS:INNMF)’s board of directors and his children are also shareholders.

During the Wednesday session, share of INNATE IMMUNOTHERA NPV (OTCMKTS:INNMF) reported a +73.50% or +$0.0258 to close the day at $0.0609.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $INNMF and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.